|
|
||||||||
Guest Access | Sign In via User Name/Password |
|||||||||
* From the Department of Pulmonary and Critical Care Medicine, Cleveland Clinic Foundation (Drs. Sarodia and Mehta), Cleveland, OH; and the Department of Pulmonary and Critical Care Medicine, Kelsey-Seybold Clinic (Dr. Dasgupta), Houston, TX.
Correspondence to: Atul C. Mehta, MBBS, FCCP, Department of Pulmonary and Critical Care Medicine, Desk A-90, The Cleveland Clinic Foundation, 9500 Euclid Ave, Cleveland, OH 44195
| Abstract |
|---|
|
|
|---|
Design: Retrospective review of medical records, and current clinical follow-up.
Setting: Tertiary care referral hospital.
Patients: All patients with airway manifestations of RP that were managed with self-expandable metallic stents at our institution.
Results: All five patients (four women and one man; age, 40 to 69 years old) had severe airway manifestations, and three of them required mechanical ventilation. Spirometry with flow-volume curves showed severe combined obstructive and restrictive ventilatory defects. Bronchoscopy revealed dynamic collapse of the proximal airways. Diagnosis was made 8 months to 13 years after the first symptom of the disease. Pharmacotherapy included prednisone, methotrexate, cyclosporine, and dapsone. A total of 17 self-expandable metallic stents of varying sizes were placed using flexible bronchoscope from 4 to 19 years after the first symptom. The overall outcome was favorable in four patients. Three patients have survived without ventilatory support 16 to 18 months following the first stent placement, and the fourth patient survived for 20 months without ventilatory support before she died. The fifth patient, who was receiving mechanical ventilation, died in 1 week probably due to persistent dynamic collapse of the airways distal to the stents.
Conclusion: Self-expandable metallic tracheobronchial stents should be considered in the management of airway manifestations of RP, especially in patients who require mechanical ventilation.
Key Words: bronchial obstruction bronchial stenosis endoscopic treatment relapsing polychondritis metal stents self-expandable stents tracheal obstruction tracheal stenosis tracheobronchomalacia Wallstent
| Introduction |
|---|
|
|
|---|
|
| Materials and Methods |
|---|
|
|
|---|
| Results |
|---|
|
|
|---|
|
In all patients, spirometry prior to specific therapy showed severe combined obstructive and restrictive ventilatory defects, and expiratory obstruction and/or inspiratory obstruction (Table 3 ). One patient had measurement of total lung capacity and diffusing capacity (69% and 44% predicted, respectively). Findings on chest radiograph and CT were unremarkable, except for narrowing of the trachea and main stem bronchi (n = 2), and atelectasis or infiltrate (n = 3; Table 2 ; Fig 1 ). Echocardiograms (n = 3) were normal, except for mild aortic insufficiency in one patient. Audiometry (n = 3) revealed bilateral sensory-neural hearing loss. The histopathology (n = 3) of cartilage from the nasal septum, trachea, or ear pinna was suggestive of RP. All patients were given diagnoses of asthma before RP was diagnosed; only two patients had a bronchodilator response. Other common comorbidities included anemia (in all patients), diabetes mellitus (n = 2), idiopathic thrombocytopenic purpura (n = 1), pseudomonas bronchitis (n = 3), and streptococcal sepsis (n = 2).
|
|
|
|
|
The complications of stent placement included cough, hemoptysis, mucus plugging, and pneumothorax. The symptom of mild, chronic, or recurrent cough persisted in all patients. Mild recurrent hemoptysis that did not require specific therapy occurred in two patients for the first few days. One patient (patient 3) developed a small right-sided pneumothorax, probably due to mucus plugging and mechanical ventilator-associated trauma. None of our patients experienced migration of the stent or developed granulation tissue that required specific therapy.
| Discussion |
|---|
|
|
|---|
Demographic and Clinical Features of RP
Cases of RP have been reported in children as well as adults, with
ages ranging from 2 to 84 years (median, 50) at the time of
diagnosis.1
2
4
The male-to-female ratio is 1:1; however,
among the patients with serious airway manifestations, females
predominate (female-to-male ratio, 2.6:1).1
2
4
Systemic
manifestations and comorbid conditions (most commonly autoimmune and
rheumatic diseases) have been well described.1
2
The
pathogenesis of the disease is unknown. Although no laboratory tests
are diagnostic, they help to rule out other diagnostic possibilities.
Histologic features of the cartilage include loss of basophilic
staining of the matrix and perichondral inflammation; eventually the
cartilage is destroyed and replaced by fibrous tissue.2
Airway Manifestations and Pulmonary Function Tests
Airway manifestations are ultimately present in about 50% of
patients with RP, although they may not be the presenting
features.1
2
They are the most serious manifestations and
predict a poor prognosis.1
4
The mechanisms of airway
obstruction include the following: (1) inflammatory swelling causing
airway narrowing in the active stage; (2) progressive destruction of
the laryngeal, tracheal, and bronchial cartilage causing dynamic
collapse of the airway in the earlier stage; and (3) formation of
fibrous tissue causing cicatricial contraction in the later
stage.8
The predominant mechanism of expiratory
obstruction is the structural abnormality of the airways, and not the
loss of lung elastic forces.9
The airway obstruction is commonly diffuse, involving the upper airways. It may be asymptomatic in earlier stages and detected only on pulmonary function testing.1 4 It is always symptomatic when it involves the glottis, subglottic area, or upper trachea. Tracheal collapse may occur suddenly causing dyspnea, respiratory arrest, asphyxia, and rapid death.6 Rarely, the obstruction may involve distal airways.10 Along with airway obstruction, impaired mucociliary clearance and diminished effectiveness of coughing may predispose these patients to develop pneumonia.8 Severe bronchorrhea may be a one of the presenting features.11
The spirometry, flow-volume curves, and airway resistance measurement together are more sensitive than bronchoscopy and radiographic imaging in determining the presence, severity, site, and nature of airway obstruction in RP.8 9 In the earlier stage, the obstruction is variable, and hence the ratio of maximal expiratory to inspiratory flow at 50% of vital capacity is either reduced (in intrathoracic obstruction) or elevated (in extrathoracic obstruction), and the resistance is normal. In the later stage, the obstruction is fixed due to cicatricial narrowing of the airway, and hence the ratio of maximal expiratory to inspiratory flow at 50% of vital capacity is close to 1, and the resistance is elevated.8 Our patients, when compared to those described in the literature, had more severe ventilatory defects as indicated by spirometry (Table 3) .8 9 This is probably because we selected only patients with stents for this study.
Radiographic Imaging
Plain radiography of the respiratory tract in patients with RP
should include a lateral view of the neck, together with a penetrated
frontal view of the chest.12
The coronal diameter of the
trachea may be smaller in patients with airway
manifestations.12
High-resolution CT scan may demonstrate
diffuse, smooth thickening of the tracheobronchial wall, causing
narrowing and deformity of the airway lumen; the airway may return to
normal with steroid therapy (Fig 1)
.4
10
12
13
14
There may
be dense calcium deposits in the tracheal wall, which may be confused
with those caused by tracheopathia osteochondroplastica and
amyloidosis.13
The CT scan is also sensitive in detecting
lower airway disease causing concentric narrowing in lobar and
segmental bronchi, and bronchiectasis in segmental and subsegmental
bronchi.10
In patients with distal airway involvement,
tracheostomy or stents to keep proximal airway patent may be of limited
value.10
Bronchoscopic Findings
Bronchoscopy is essential in identifying the exact site, nature,
and severity of airway involvement in RP. It usually reveals
inflammation of the tracheobronchial tree, and dynamic collapse or
narrowing of the major airways (Fig 2)
. These findings are more common
in patients with expiratory obstruction than in patients with
inspiratory obstruction.9
Bronchoscopy does carry a risk
of provoking dyspnea, collapse of the airways, hypoxia, asphyxia, and
death.4
Treatment
No single medical or surgical treatment is uniformly effective in
curing the disease, relieving the symptoms, or preventing progression
of airway manifestations. Most patients with airway manifestations are
managed with pharmacologic and supportive treatment. The medications
tried in single patients or in small series of patients, with variable
response, include nonsteroidal anti-inflammatory drugs (aspirin,
indomethacin, and phenylbutazone), corticosteroids, and other
immunosuppressive medications (cyclosporine, methotrexate,
azathioprine, penicillamine, 6-mercatopurine, and
dapsone).1
2
3
4
15
Corticosteroids decrease the frequency,
duration, and severity of flares, but do not stop disease progression
in severe cases.2
The risk-benefit ratio for use of these
medications in RP is not well established, and hence they are not
recommended for routine use.
Surgical treatments include the following: tracheostomy, tracheobronchial (intraluminal) stents, external airway splinting, and laryngotracheal reconstruction.4 5 Tracheostomy, if performed early, may prevent sudden death in patients with localized subglottic involvement. However, tracheostomy itself may be hazardous by making the intubation difficult in the future.5
Self-expandable metallic airway stents, as shown in this report, can be used as the sole specific treatment or as an adjunct to other treatment modalities.7 Advantages of a metallic stent include the following: (1) ease of placement; (2) visibility on ordinary radiograph (Fig 3) ; (3) dynamic expandability; and (4) maintenance of ventilation even when a bronchial orifice is covered by the stent.16 Additional advantages offered by a SEMS (eg, Wallstent) include the following: (1) it can be placed by a FB in an outpatient setting under local anesthesia and conscious sedation, avoiding hospitalization and general anesthesia; (2) it can be placed in a patient receiving mechanical ventilation; (3) epithelialization of the stent occurs in few weeks after placement, which preserves mucociliary action and lowers the risk of mucus plugging; (4) it rarely migrates; (5) it conforms to a tortuous airway; and (6) it allows intubation through a tracheal stent, with a tracheostomy tube or with an endotracheal tube, if necessary (Fig 3) .7 16 Complications of stents in general include migration, granulation tissue formation, retention of secretions, bleeding, ulceration, and, rarely, erosion of the tracheobronchial wall into the surrounding structures.7 16 One of the disadvantages of a SEMS is that once it is placed, it cannot be removed without significant morbidity.16 Stent placement is best performed early in the course of RP, rather than after prolonged mechanical ventilation that can promote tracheobronchial colonization with pseudomonas or other organisms.6 17
External airway splinting using other tissues of the body or Gore-Tex (A. L. Gore; Flagstaff, AZ) is the treatment of choice to prevent collapse in cases of severe tracheobronchial disease.4 Laryngotracheal reconstruction is considered when tracheal or subglottic stenosis occurs in isolated segments; however, the reported benefits are limited.5 During general anesthesia, the anesthetist should be aware of the degree of airway and cardiovascular involvement.6 18 The use of corticosteroids in the perioperative period may help by reducing inflammation.6 Tracheal collapse may be prevented by applying continuous positive airway pressure with a mask, by awake intubation with the patient in an upright position, or by intubating over a bronchoscope.6
Prognosis
The course of RP may be relatively benign and indolent, or it may
be rapidly fatal even after pharmacologic treatment, tracheostomy, and
tracheobronchial stent placement.1
4
6
Death is directly
attributable to RP in about half of the fatal cases. Survival rates for
5 and 10 years are 74% and 55% respectively.1
Reported
death from respiratory tract involvement varies from 10% (4 of 41) to
59% (17 of 29) of total deaths.1
2
In a series,
laryngotracheal stricture was one of the three variables (the other two
being age and anemia) that predicted mortality on multivariate
analysis.1
Summary
Unexplained dyspnea, stridor, hearing deficit, and recurrent ear
or nasal inflammation with deformity may be early manifestations of RP.
Physicians should have a high index of suspicion in the presence of
these manifestations for the early diagnosis and treatment of this rare
disease. No single medical or surgical treatment is uniformly effective
in curing the disease, in relieving the symptoms, or in preventing the
progression of airway manifestations. The management of airway
manifestations of RP with self-expandable metallic tracheobronchial
stents may provide a long-term palliation. A multidisciplinary team
approach by pulmonologists, otolaryngologists, rheumatologists,
thoracic surgeons, and interventional radiologists is required for the
efficient management of these patients. Further studies are required to
determine the ideal type of stent and the optimal timing of its
placement to prevent long-term morbidity and mortality from the airway
manifestations of RP.
| Acknowledgements |
|---|
| Footnotes |
|---|
Received for publication February 25, 1999. Accepted for publication May 19, 1999.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
K. S. Lee, A. Ernst, D. E. Trentham, W. Lunn, D. J. Feller-Kopman, and P. M. Boiselle Relapsing Polychondritis: Prevalence of Expiratory CT Airway Abnormalities Radiology, August 1, 2006; 240(2): 565 - 573. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. H. Thornton, R. L. Gordon, R. K. Kerlan, J. M. LaBerge, M. W. Wilson, K. A. Wolanske, M. B. Gotway, G. S. Hastings, and J. A. Golden Outcomes of tracheobronchial stent placement for benign disease. Radiology, July 1, 2006; 240(1): 273 - 282. [Abstract] [Full Text] [PDF] |
||||
![]() |
Management of tracheomediastinal fistulas using self-expanding metallic stents. J. Thorac. Cardiovasc. Surg., March 1, 2006; 131(3): 748 - 749. |
||||
![]() |
Y. Miyazu, T. Miyazawa, N. Kurimoto, Y. Iwamoto, A. Ishida, K. Kanoh, and N. Kohno Endobronchial Ultrasonography in the Diagnosis and Treatment of Relapsing Polychondritis With Tracheobronchial Malacia Chest, December 1, 2003; 124(6): 2393 - 2395. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. P. Saad, S. Murthy, G. Krizmanich, and A. C. Mehta Self-Expandable Metallic Airway Stents and Flexible Bronchoscopy: Long-term Outcomes Analysis Chest, November 1, 2003; 124(5): 1993 - 1999. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Schneider, J. Grone, J. Braun, A. Perez-Canto, and H. J Buhr Wegener's Granulomatosis Presenting as Necrosis of the Left Mainstem Bronchus Asian Cardiovasc Thorac Ann, September 1, 2002; 10(3): 277 - 279. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. V. Behar, Y.-W. Choi, T. A. Hartman, N. B. Allen, and H. P. McAdams Relapsing Polychondritis Affecting the Lower Respiratory Tract Am. J. Roentgenol., January 1, 2002; 178(1): 173 - 177. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. M. Seijo and D. H. Sterman Interventional Pulmonology N. Engl. J. Med., March 8, 2001; 344(10): 740 - 749. [Full Text] [PDF] |
||||
![]() |
P. Luckey, J. Kemper, T. Niehues, H. Schroten, and G. Fürst Diagnostic Role of Inspiration and Expiration CT in a Child with Relapsing Polychondritis Am. J. Roentgenol., January 1, 2001; 176(1): 61 - 62. [Full Text] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |